Core Insights - Lyell Immunopharma is advancing its pipeline of next-generation CAR T-cell therapies, specifically focusing on IMPT-314 for aggressive large B-cell lymphoma, which is set to enter pivotal trials [1][2][4] Pipeline Focus - The company is dedicated to developing CAR T-cell therapies that aim to achieve higher response rates and longer durations of response for patients with hematologic malignancies and solid tumors [3] - IMPT-314 is designed to target B-cells expressing either CD19, CD20, or both, utilizing a dual-targeting approach to enhance treatment efficacy compared to existing therapies [4][12] Clinical Data and Development Plans - Initial clinical data from 23 patients indicated an overall response rate of 94% and a complete response rate of 71% in the 3rd-line+ setting, with a median follow-up of 6.3 months [14] - The company plans to initiate pivotal trials for IMPT-314 in the 3rd-line+ setting in 2025 and in the 2nd line by early 2026 [6][17] Financial Outlook - Lyell expects a net cash use of $175 million to $185 million for 2025, which will extend its cash runway into 2027, supporting multiple clinical milestones [9] - The company is streamlining operations and discontinuing the development of LYL119 to focus resources on IMPT-314 and next-generation solid tumor CAR T-cell programs [8] Upcoming Milestones - Additional data from the ongoing Phase 1-2 trial is expected to be presented in mid-2025, including more mature data from the 3rd line+ cohort and initial data from the 2nd line cohort [7] - The first IND application for a new solid tumor CAR T-cell product candidate is anticipated to be submitted in 2026 [8]

Core Viewpoint - Lyell Immunopharma (LYEL) has experienced significant selling pressure, resulting in a 31.2% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1]. Group 1: Stock Performance and Technical Analysis - The stock is currently in oversold territory, indicated by an RSI reading of 28.44, suggesting that the heavy selling may be exhausting itself [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2]. - Technical analysis indicates that stocks oscillate between overbought and oversold states, and the RSI can signal potential price reversals [3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for LYEL, resulting in a 0.9% increase in the consensus EPS estimate over the last 30 days [7]. - LYEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].

Core Viewpoint - Lyell Immunopharma (LYEL) has experienced a significant decline of 30.9% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal supported by analyst consensus for better-than-expected earnings [1]. Technical Analysis - The Relative Strength Index (RSI) for LYEL is currently at 26.76, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a reversal towards the old equilibrium of supply and demand [5]. - RSI is a momentum oscillator that ranges from 0 to 100, with readings below 30 indicating that a stock is considered oversold [2][3]. Fundamental Analysis - Over the last 30 days, the consensus earnings per share (EPS) estimate for LYEL has increased by 2.5%, indicating a positive trend in earnings estimate revisions, which typically correlates with price appreciation [7]. - LYEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further supporting the potential for a turnaround [8].

Core Viewpoint - Lyell Immunopharma (LYEL) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - For the fiscal year ending December 2024, Lyell Immunopharma is projected to earn -$0.80 per share, reflecting a 14% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Lyell Immunopharma has increased by 6.3%, indicating a positive trend in earnings expectations [8]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock price movements, as they adjust their valuations based on these estimates, leading to significant buying or selling actions [4]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Lyell Immunopharma to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Table of Contents __________________________ __________________________ __________________________ __________________________ __________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 • Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell nonHodgkin's lymphoma • Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024 (ASH) Annual Meeting • Pr ...

Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line setting with B-cell non-Hodgkin lymphoma who have not yet been exposed to CAR T-cell therapySumant Ramachandra, M.D., Ph.D., MBA, appointed to Lyell’s Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell ...

Company Overview - Lyell Immunopharma is a clinical-stage T-cell reprogramming company focused on developing cell therapies for solid tumors and hematologic malignancies [3] - The company has three product candidates in or entering Phase 1 clinical development [3] - Lyell's proprietary technology addresses T-cell exhaustion and lack of durable stemness to improve clinical outcomes [3] - The company is headquartered in South San Francisco, California with additional facilities in Seattle and Bothell, Washington [3] Upcoming Event - Lyell's President & CEO, Lynn Seely, MD, will participate in a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1, 2024, at 11:50 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible after the live event [2]

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th at 10:45 am Eastern Time H.C. Wainw ...

Table of Contents __________________________ __________________________ __________________________ __________________________ __________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) ...